FINVECTOR OY

Their core work

Finvector Oy is a Finnish gene therapy company based in Kuopio specializing in the development and manufacturing of viral vectors used in clinical-stage gene therapy programs. Their core contribution to EU research has been providing the vector production and development expertise needed to take cardiovascular gene therapies from laboratory concept into human clinical trials. In both H2020 projects they supported therapeutic programs targeting heart disease — first a VEGF-D-based regenerative therapy for angina, then a next-generation approach using non-coding RNA. As a private company embedded in clinical consortia, they represent the industrial manufacturing bridge between academic discovery and patient-ready therapeutic products.

What they specialise in

How they've shifted over time

In their first H2020 project (ReGenHeart, starting 2017), Finvector's work centered on a specific and relatively mature therapeutic concept — VEGF-D protein delivery for regenerating heart tissue in angina patients, with a clear clinical trial focus and regenerative medicine framing. By their second project (CardioReGenix, starting 2019), the regenerative medicine language dropped away and ncRNA emerged as a new modality alongside gene therapy, reflecting a shift toward next-generation molecular tools rather than protein-based approaches. The trajectory suggests Finvector is broadening its vector and payload capabilities beyond first-generation gene therapy constructs into RNA-targeting strategies.

Finvector appears to be moving from single-modality viral vector manufacturing toward multi-platform gene and RNA therapy production, making them a relevant partner for consortia exploring RNA-based cardiovascular or rare disease programs.

How they like to work

Finvector has participated exclusively as a consortium partner rather than a project coordinator across both H2020 projects, consistent with a specialist industrial partner contributing defined manufacturing or development capabilities rather than leading scientific programs. Despite only two projects, they have engaged with 20 distinct partners across 9 countries, suggesting participation in relatively large, multi-partner RIA consortia — typical for clinical-stage gene therapy programs that require coordinated academic, clinical, and manufacturing nodes. This profile points to an organisation comfortable operating as a technical service provider within scientifically-led consortia.

Finvector has built connections with 20 unique partners across 9 countries from just two projects, which implies integration into sizable international consortia — a breadth unusual for an organisation with so few projects. No dominant geographic cluster is evident from the available data, suggesting their partners span multiple EU member states typical of large H2020 health RIAs.

What sets them apart

Finvector occupies a narrow but strategically important niche as a Finnish private-sector gene therapy company providing industrial vector development and manufacturing capacity within academic-led clinical consortia — a role that universities and hospitals in the same programs cannot fill themselves. Their location in Kuopio, part of Finland's established biotech corridor, and their consistent focus on cardiovascular targets gives them credibility in a therapeutic area where clinical translation bottlenecks are well known. For a consortium building a cardiovascular or rare disease gene therapy program that needs a manufacturing partner with clinical-grade experience, Finvector offers both the technical capability and a track record of operating inside complex EU-funded trials.

Highlights from their portfolio

• ReGenHeart
  The largest single grant Finvector has received (EUR 616,967) and the project that placed them inside a clinical-stage VEGF-D gene therapy trial for angina — a high-value proof-of-concept program running five years to 2022.
• CardioReGenix
  Signals Finvector's pivot toward next-generation gene therapy using non-coding RNA, extending their capabilities beyond classical protein-coding constructs into an emerging therapeutic modality.